Development of Sanofi Pasteur tetravalent dengue vaccine

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 54, Issue SUPPL.18, 2012, Pages 15-17

  Lang, Jean ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

ARTICLE; BRAZIL; DENDRITIC CELL; DENGUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INSECTICIDE RESISTANCE; NONHUMAN; PUBLIC HEALTH; SEROTYPE; VACCINATION; VECTOR CONTROL; VIREMIA; VIRUS VIRULENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84867113170     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652012000700007     Document Type: Article

References (17)

1. World Health Organization. Dengue. [Cited: 13 Jan. 2012]. Available from: http://www.who.int/.
2. Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccin. 2010;6:745-53.
3. San Martin JL, Brathwaite O, Zambrano B, Solorzano JO, Bouckenooghe A, Dayan GH, et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010;82:128-35.
4. Siqueira Jr JB, Vinhal LC, Said RFC, Hoffmann JL, Martins J, Barbiratto SB, et al. Dengue no Brasil: tendências e mudanças na epidemiologia, com ênfase nas epidemias de 2008 e 2010. Brasília: Portal da Saúde. [Cited: 20 Jan. 2010]. Available from: url www. saude.gov.br.
5. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg. 2009;80:846-55.
6. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29:7276-84.
7. Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin. 2010;6:696-705.
8. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From esearch to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29:7229-41.
9. st Dengue v2V Asia-Pacific Meeting. Vaccine. 2011;29:9417-22.
10. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol. 2010;338:129-43.
11. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632-49.
12. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naïve adults. J Infect Dis. 2010;201:370-7.
13. Guy B, Almond J, Lang J. Dengue vaccine prospects: a step forward. Lancet. 2011;377(9763):381-2.
14. th Annual Meeting Abstract Book].
15. Barban V, Girerd Y, Aguirre M, Gulia S, Pétiard F, Riou P, et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine. 2007;25:2941-50.
16. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30:A9-A10.
17. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29:3863-72.